ANCA-Associated Vasculitis (AAV): What It Is, Why Blood Vessels Become Inflamed, and How Treatment Prevents Organ Damage
Updated: 2 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: September 2026
Editorial note: This article is for general education only. It is not medical advice, a diagnosis, or a treatment plan. ANCA-associated vasculitis is a group of rare, potentially serious autoimmune diseases that require diagnosis and ongoing management by a rheumatologist or other specialist. If you have symptoms of vasculitis, talk to a healthcare provider. Coughing up blood, sudden trouble breathing, or a new severe symptom is a medical emergency — call 911.
TL;DR
ANCA-associated vasculitis (AAV) is a group of three rare autoimmune diseases — GPA, MPA, and EGPA — in which the immune system produces antibodies (ANCAs) that mistakenly attack small and medium blood vessels. This causes inflammation, thickened vessel walls, and reduced blood flow that can damage the kidneys, lungs, sinuses, skin, nerves, and other organs. AAV affects roughly 200 to 400 people per million worldwide, most often appears between ages 65 and 74, and can involve the kidneys in up to 80–90% of cases. There is no cure, but corticosteroids combined with rituximab, cyclophosphamide, or other immunosuppressants can bring most people into remission — about 90% of people with GPA achieve remission with treatment — though relapse affects roughly 30 to 50% of patients over time.
Quick Answer: What Is ANCA-Associated Vasculitis?
ANCA-associated vasculitis (AAV) is a group of three rare autoimmune diseases that cause inflammation and damage in small and medium blood vessels throughout the body [1]. "ANCA" stands for antineutrophil cytoplasmic antibodies — antibodies that normally help identify and destroy invading germs, but in AAV mistakenly target the body's own healthy tissue [1]. The resulting inflammation makes blood vessels swell and thicken, making it harder for blood to flow and, over time, damaging the vessels and the organs they supply — most often the kidneys, lungs, sinuses, skin, nerves, joints, and heart [1]. AAV is rare, usually diagnosed between ages 65 and 74, and requires long-term, often lifelong, management [2] [10].
What Causes ANCA-Associated Vasculitis?
AAV is an autoimmune disease, meaning the immune system attacks the body's own tissue instead of protecting it — but exactly what triggers this in any individual person isn't certain [1]. Most people with AAV have ANCAs circulating in their blood, and some researchers believe these antibodies can directly trigger the disease process [1]. However, the relationship isn't perfectly clean: not everyone with AAV tests positive for ANCAs, and some people carry ANCAs in their blood without ever developing vasculitis [1]. This is why AAV is generally described as immune-mediated rather than fully explained by antibody levels alone.
Two main ANCA subtypes are associated with the disease: PR3-ANCA, found in roughly 60–70% of people with GPA, and MPO-ANCA, found in about 40–50% of people with MPA and around 40% of people with EGPA [5] [11]. Whatever the trigger, the downstream effect is the same: inflamed, thickened vessel walls restrict blood flow, and the tissues those vessels feed become starved of oxygen and nutrients, which is what ultimately causes organ damage [1].
ANCA-associated vasculitis develops when antineutrophil cytoplasmic antibodies mistakenly target small and medium blood vessels, causing inflammation that thickens vessel walls and restricts blood flow. The disease encompasses three related subtypes — GPA, MPA, and EGPA — that share this mechanism but differ in which organs are most affected. AAV is rare, affecting an estimated 200 to 400 people per million worldwide, and most often develops between the ages of 65 and 74.
The Three Types of ANCA-Associated Vasculitis
AAV isn't a single disease — it's an umbrella term for three related conditions that share the same underlying autoimmune mechanism but differ in which organs are typically involved and how they tend to present [1].
Type | Also known as | Approximate share of AAV cases |
Granulomatosis with polyangiitis (GPA) | Formerly Wegener's granulomatosis | ~45% [12] |
Microscopic polyangiitis (MPA) | — | ~25% [12] |
Eosinophilic granulomatosis with polyangiitis (EGPA) | Formerly Churg-Strauss syndrome | ~10% [12] |
GPA is the most common of the three and is especially associated with sinus, lung, and kidney involvement. MPA more frequently and more severely affects the kidneys. EGPA is distinguished by asthma and elevated eosinophils (a type of white blood cell) alongside vasculitis [1] [12].
How Common Is ANCA-Associated Vasculitis?
AAV is considered a rare disease, but estimates of exactly how common it is vary depending on the population studied and the methodology used [3] [4].
Measure | Estimate | Source |
Worldwide prevalence | ~200–400 cases per million people | Almaani et al., Clin Kidney J 2021 [3] |
US incidence | ~3.3 new cases per 100,000 people per year | ACR 20-year population-based study [4] |
US prevalence | ~42 cases per 100,000 people | ACR 20-year population-based study [4] |
GPA prevalence | ~210 cases per million people | Hellmich et al. 2021 [5] |
MPA prevalence | ~46 cases per million people | Hellmich et al. 2021 [5] |
Most common age at diagnosis | 65–74 years old | GARD [2] |
AAV can occur at any age, but it's most commonly diagnosed in people in their mid-60s to mid-70s, and research suggests a slightly higher risk in males [1] [2].
Who Is at Risk?
Anyone can develop ANCA-associated vasculitis, and researchers haven't identified a single clear cause that explains why it develops in a given person [1]. That said, a few patterns are well established:
Risk factor | What's known |
Age | Most commonly diagnosed between ages 65 and 74, though it can occur at any age [2] |
Sex | Slightly higher risk in males [1] |
ANCA antibodies | Most people with AAV have detectable ANCAs, though not everyone does [1] |
What Are the Symptoms?
Symptoms of AAV vary widely depending on the type and which organs are affected, and they often start out vague — fatigue, low-grade fever, and a general sense of feeling unwell — before becoming more specific [1].
Symptom category | Examples |
General/whole-body | Fever, fatigue, feeling generally unwell, unexplained weight loss, loss of appetite [1] |
Skin | Rashes or discolored patches [1] |
Respiratory | Shortness of breath, coughing, coughing up blood [1] |
Ears, nose, sinuses | Nasal polyps, pain in the nose or sinuses [1] |
Musculoskeletal | Pain in muscles or joints, muscle weakness [1] |
Nervous system | Numbness or tingling [1] |
Cardiovascular | Heart palpitations, chest pain [1] |
Kidneys | Blood in urine [1] |
Digestive | Blood in stool [1] |
Kidney involvement is especially common — affecting an estimated 80% of people with GPA and up to 90% of people with MPA — which is one reason routine urinalysis and blood testing play such a central role in both diagnosis and ongoing monitoring [1] [4].
Symptoms of AAV can affect nearly any organ system, but the kidneys and lungs are involved especially often — kidney involvement occurs in an estimated 80% of GPA cases and up to 90% of MPA cases. Coughing up blood, sudden shortness of breath, or a new severe symptom alongside fever are emergency warning signs that require immediate medical attention, since AAV can progress quickly without treatment.
What Complications Can ANCA-Associated Vasculitis Cause?
Left untreated, AAV can cause serious, potentially life-threatening damage to the organs it affects [1]. Recognizing these risks is part of why early diagnosis and treatment matter so much.
Complication | Why it happens |
Lung bleeding | Inflamed lung blood vessels can rupture [1] |
Pulmonary fibrosis | Chronic inflammation leads to permanent lung scarring [1] |
Nerve damage | Inflamed vessels supplying nerves restrict blood flow to nerve tissue [1] |
Kidney failure | Ongoing inflammation damages kidney filtering units; occurs in an estimated 10–20% of cases despite treatment [1] [4] |
Heart failure | Vessel damage can impair the heart's ability to pump effectively [1] |
How Is ANCA-Associated Vasculitis Diagnosed?
Diagnosing AAV typically starts with a physical exam and a detailed symptom history, and because early symptoms can resemble many other conditions, providers usually need to rule out more common explanations first [1]. A rheumatologist typically leads the diagnostic process, bringing in other specialists — such as a nephrologist for kidney involvement or a pulmonologist for lung involvement — as needed [1].
Test | What it looks for |
Blood tests (including the ANCA test) | Antineutrophil cytoplasmic antibodies and markers of inflammation and organ function [1] |
Urinalysis | Blood or protein in the urine, signs of kidney involvement [1] |
Chest X-ray | Lung involvement, including nodules or scarring [1] |
MRI or CT scan | Detailed imaging of affected organs and tissues [1] |
Angiogram | Detailed imaging of blood vessels [1] |
How Is ANCA-Associated Vasculitis Treated?
There's no cure for AAV, so treatment focuses on two goals: controlling active inflammation to prevent organ damage, and then maintaining remission for as long as possible [1]. Treatment typically starts at a relatively high dose to bring the disease under control, then is adjusted downward once remission — little to no inflammation — is achieved [1].
Treatment | How it works |
Corticosteroids | Reduce inflammation and suppress immune activity; usually the first medication started [1] |
Rituximab | Targets the immune cells that produce ANCAs, typically used alongside corticosteroids [1] |
Cyclophosphamide | A chemotherapy drug used at lower doses for vasculitis, alongside corticosteroids [1] |
Other immunosuppressants | Additional medications to help control the immune response [1] |
The exact combination and duration of treatment depends on which type of AAV a person has, which organs are involved, and how severe the disease is at diagnosis [1]. With treatment, about 90% of people with GPA achieve remission — though untreated GPA has a mortality rate as high as 80%, which underscores how important timely treatment is [9].
Treatment for AAV typically begins with corticosteroids alongside rituximab or cyclophosphamide to control inflammation and induce remission, then shifts to lower maintenance doses to sustain it. About 90% of people with GPA achieve remission with modern treatment, but relapse is common — affecting an estimated 30 to 50% of people with AAV over time — which is why long-term, often lifelong, follow-up care is standard.
When to See a Provider or Go to the ER
Because AAV can progress quickly and affect vital organs, knowing when to seek urgent care is important [1].
Seek care from your provider if | Go to the ER or call 911 if |
Your symptoms change or worsen | You're coughing up blood |
Your current treatment doesn't seem to be working | You can't breathe |
You develop new symptoms that concern you | You develop new, severe, concerning symptoms |
— | You have a fever alongside other symptoms |
What's the Outlook for ANCA-Associated Vasculitis?
AAV is a long-term — sometimes lifelong — condition that requires ongoing management, but outcomes have improved substantially with modern treatment [1] [10].
Measure | Estimate | Source |
5-year survival, GPA | ~74–81% | Bataille et al. 2022 [8]; Medscape [10] |
5-year survival, MPA | ~72% | Bataille et al. 2022 [8] |
Overall AAV 5-year survival | ~70–80% | Rare Disease Advisor [7] |
Remission with treatment (GPA) | ~90% | Panupattanapong 2018 [9] |
Relapse, AAV overall | ~30–50% | Rare Disease Advisor [6] |
Relapse, GPA (lifetime risk) | Up to ~50% | Cleveland Clinic [1]; Rare Disease Advisor [7] |
Relapse, MPA | ~1 in 3, median time to relapse 15–43 months | Rare Disease Advisor [7] |
Relapse is most common in GPA, and mortality risk is highest in the first several months after diagnosis, which is why close monitoring early in treatment matters [1]. With sustained treatment and follow-up, though, many people achieve remission that lasts months to years at a time [1].
Key Takeaways
ANCA-associated vasculitis (AAV) is a group of three rare autoimmune diseases — GPA, MPA, and EGPA — in which antibodies mistakenly attack small and medium blood vessels [1].
The kidneys and lungs are especially often affected, with kidney involvement occurring in an estimated 80% of GPA cases and up to 90% of MPA cases [1] [4].
AAV is rare, affecting roughly 200 to 400 people per million worldwide, and is most often diagnosed between ages 65 and 74 [2] [3].
There's no cure, but corticosteroids combined with rituximab, cyclophosphamide, or other immunosuppressants bring most people into remission — about 90% of people with GPA achieve remission with treatment [1] [9].
Relapse is common, affecting an estimated 30 to 50% of people with AAV, which is why long-term follow-up care is standard [6] [7].
Coughing up blood, sudden trouble breathing, or a new severe symptom with fever are emergency warning signs [1].
Frequently Asked Questions
Is ANCA-associated vasculitis the same as Wegener's granulomatosis? Wegener's granulomatosis is the former name for granulomatosis with polyangiitis (GPA), which is one of the three types of AAV [1].
Is ANCA-associated vasculitis curable? No, there's currently no cure, but treatment can bring most people into remission — a state of little to no inflammation — that can last for months or years [1].
Is ANCA-associated vasculitis hereditary? AAV is an autoimmune disease with an uncertain cause, and while family history of autoimmune conditions can play a role in some diseases, AAV is not considered a directly inherited condition [1].
Can ANCA-associated vasculitis go away on its own? No. Without treatment, AAV can progress and cause serious organ damage. Untreated GPA, for example, has been associated with mortality rates as high as 80% [9]. Treatment is essential for achieving and maintaining remission.
What's the difference between GPA, MPA, and EGPA? All three are types of AAV that share the same underlying mechanism — antibodies attacking blood vessels — but differ in typical organ involvement. GPA commonly affects the sinuses, lungs, and kidneys; MPA tends to affect the kidneys most severely; and EGPA is marked by asthma and elevated eosinophils alongside vasculitis [1] [12].
Read More From Our Health Library
References
Cleveland Clinic. "ANCA-Associated Vasculitis." https://my.clevelandclinic.org/health/diseases/anca-vasculitis
Genetic and Rare Diseases Information Center (GARD). "Anti-neutrophil cytoplasmic antibody-associated vasculitis." https://rarediseases.info.nih.gov/diseases/13011/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis
Almaani S, et al. "ANCA-associated vasculitis: an update." Clinical Kidney Journal, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8037363/
American College of Rheumatology. "The Epidemiology of ANCA-Associated Vasculitis in the U.S.: A 20-Year Population-Based Study." https://acrabstracts.org/abstract/the-epidemiology-of-anca-associated-vasculitis-in-the-u-s-a-20-year-population-based-study/
Hellmich B, et al. Epidemiology of ANCA-associated vasculitis. PubMed, 2021. https://pubmed.ncbi.nlm.nih.gov/33501936/
Rare Disease Advisor. "ANCA-Associated Vasculitis Epidemiology." https://www.rarediseaseadvisor.com/disease-info-pages/anca-associated-vasculitis-epidemiology/
Rare Disease Advisor. "ANCA-Associated Vasculitis Prognosis." https://www.rarediseaseadvisor.com/disease-info-pages/anca-associated-vasculitis-prognosis/
Bataille P, et al. Survival in ANCA-associated vasculitis. Clinical Immunology, 2022. https://pubmed.ncbi.nlm.nih.gov/36108505/
Panupattanapong S, et al. Outcomes in granulomatosis with polyangiitis. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6258356/
Medscape. "Granulomatosis With Polyangiitis (Wegener Granulomatosis)." https://emedicine.medscape.com/article/332622-overview
Hunter RW, Welsh N, Farrah TE, et al. "ANCA associated vasculitis." BMJ. 2020;369:m1070.
Merck Manual Professional Version. "Overview of Vasculitis."
Qasim A, Patel JB. "ANCA-Associated Vasculitis." StatPearls, 2024. https://www.ncbi.nlm.nih.gov/books/NBK559189/
Comments